• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cv Sciences Inc (OP: CVSI )

    0.0479 +0.0029 (+6.44%)
    Streaming Delayed Price Updated: 3:52 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cv Sciences Inc

    < Previous 1 2 3 4 5 6 7 8 Next >
    Popular CBD Brand Questions Study: 'Misleading To Consumers And Damaging To The Industry'
    NextEvo Naturals recently released results from a third-party study on 16 CBD products that were allegedly randomly selected for the research. The brand commissioned Coral Reef Labs to conduct this... 
    Via Benzinga
    CV Sciences FY22 Revenue Declines 19% To $16.2M
    CV Sciences, Inc. (OTCQB: CVSI) FY 2022 revenue was $16.2 million, a 19% decrease compared to $20.0 million for 2021. Q4 2022 Financial Highlights 
    Via Benzinga
    CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next
    CV Sciences, Inc. (OTCQB: CVSI) received a formal certificate of grant from the Japan Patent Office for its patent application 7216697. 
    Via Benzinga
    Why Is CV Sciences Stock Up Today?
    CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results. 
    Via Benzinga
    Biden's Pardon For Cannabis Offenders: 27 Reactions From Politicians, Industry Executives And Advocacy Orgs
    President Joe Biden announced on Thursday that he will pardon all prior federal offenses for simple marijuana possession, sending  
    Via Benzinga
    CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products
    CV Sciences, Inc. (OTCQB:CVSI) added +PlusCBD ... 
    Via Benzinga
    Nutrition Giant GNC To Distribute CBD Products In 770 Stores In US
    Hemp cannabidiol (CBD) products maker CV Sciences, Inc. (OTCQB: 
    Via Benzinga
    The CBD Gold Rush Is Over (And That's A Great Thing For Consumers)
    By Bharat Ayyar Disclaimer: I am not a financial advisor. Nothing contained in this post should be construed as investment advice. CV Sciences (OTC: CVSI), the company behind +PlusCBD, had a meteoric... 
    Via Benzinga
    Marijuana As An Appetite Suppressant? It's A Possibility
    Using cannabis as an appetite suppressant for weight management may seem counterintuitive, but one rare cannabinoid may have just that effect. Delta-9 (d-9)-dominant tetrahydrocannabivarin (THCV) has... 
    Via Benzinga
    CV Sciences Q1 Revenue Down 8.33%, CEO Encouraged As PlusCBD Brand Gains Market Share
    CV Sciences, Inc. (OTCQB: CVSI) released its financial results for the quarter ended March 31, 2022, revealing a revenue drop of 8.33% to $4.4 million YoY. First Quarter 2022 and Recent Financial and... 
    Via Benzinga
    A Preview Of CV Sciences's Earnings
    CV Sciences (OTC:CVSI) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that CV Sciences will... 
    Via Benzinga
    Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
    After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in 
    Via Benzinga
    CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
    CV Sciences, Inc. (OTCQB:CVSI) is launching +PlusCB... 
    Via Benzinga
    Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
    The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI ... 
    Via Benzinga
    The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
    Below is a recap of the main news related to the cannabis industry and markets for the week of November 15, 2021. 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Trending Up: $TLLTF $VRNOF $UNRV, GOP Cannabis Bill, Cause for Hope? — Cannabis Daily November 16, 2021
    The Best Daily Overview Of The Cannabis Space Representativ... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation
    CV Sciences, Inc. (OTCQB:CVSI), a supplier and manufacturer... 
    Via Benzinga
    Topics Supply Chain
    Exposures Supply Chain
    Pharmaceutical & Hemp Wellness Segments Of Cannabidiol Market Could See the Fastest Growth Rates Through 2028
    Palm Beach, FL – November 15, 2021 – FinancialNewsMedia.com News Commentary – Out of all cannabinoids, cannabidiol is most widely used for therapeutic reasons due to the lack of psychoactive effects.... 
    Via FinancialNewsMedia
    Earnings Preview For CV Sciences
    CV Sciences (OTC:CVSI) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement. Analysts estimate... 
    Via Benzinga
    EXCLUSIVE: CV Sciences Launches New Product Line Featuring Full Range Of Phytocannabinoids
    CV Sciences Inc (OTC:CVSI) is launching a ne... 
    Via Benzinga
    Looking Into CV Sciences's Return On Capital Employed
    CV Sciences (OTC:CVSI) brought in sales totaling $5.13 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 12.75%, resulting in a loss of $3.... 
    Via Benzinga
    Ryder Cup To Retirees: Many Golfers Say CBD Is A Hole In One For Their Game
    Professional golf is one of, if not the most cannabis-friendly globally played sports today. While Olympians and athletes in other sports cont... 
    Via Benzinga
    Cantor Remains Neutral on Charlotte's Web, cbdMD and CV Science CBD Stocks, Sector Could Benefit From Federal Legalization
    Cantor Fitzgerald released a new report analyzing the possible effects of CBD reform in the stock performance of Charlotte... 
    Via Benzinga
    American Cannabis Operator Index Lost 0.6% This Year, Best Players In July: Columbia Care, Lowell Farms, Ayr Wellness & Ascend Wellness
    The American Cannabis Operator Index declined for the fifth straight month falling 10.7% to 62.66. The index, which launched in Oc... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Slight Correction For Cannabis Stocks After A Ramping Week, Check Out The Top Movers For July 30, 2021
    GAINERS: Rhinomed (OTC: 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    The Week In Cannabis: Amazon Lobbies In DC, Colombia's New Law, Big IPOs And More
    Below is a recap of the main news related to the cannabis industry and markets for the week of July 16, 2021. 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Watch Planet 13's CEO & Matt Hawkins From Entourage Effect Capital At Benzinga Cannabis Hour 7/21
    Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday's show, hosts Elliot L... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    CBD Can Reduce Nicotine Withdrawal Symptoms, Says New Study Done By CV Sciences
    This week, CV Sciences (OTCQB:CVSI) released the results of... 
    Via Benzinga
    Australis, CV Sciences And MedMen Among Top Cannabis Stock Movers On July 9, 2021
    GAINERS: Livewell Canada Inc (OTC: 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour
    Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.